Officer Francis Lo Files Intent to Sell $4.27M in Stock
ADPT has more than doubled off its 52-week low of $9.955.
Summary
An officer at Adaptive Biotechnologies has filed an intent to sell over $4 million in company stock, primarily from compensation, adding to recent insider selling activity.
Key Events · Ownership and Investor Activity · ADPT
-
Officer Files Intent to Sell Shares
Officer Francis Lo has filed a Form 144 to sell 199,260 shares of common stock, valued at approximately $4.27 million. These shares were acquired through the exercise of stock options and vesting of restricted stock units.
-
Follows Recent Insider Sales
This proposed sale by Mr. Lo follows previous sales of 62,305 shares totaling over $1 million in the past three months, and aligns with a broader pattern of insider distribution noted in recent activity.
-
Stock Trading Above 52-Week High
The intent to sell comes as Adaptive Biotechnologies' stock is trading above its 52-week high of $22.54, potentially indicating profit-taking by the officer.
Analysis · ADPT · Life Sciences
Officer Francis Lo has filed a Form 144 indicating an intent to sell approximately $4.27 million worth of common stock. This proposed sale, primarily from exercised stock options and vested restricted stock units, follows previous sales by Mr. Lo and other insiders, contributing to a broader pattern of insider distribution. The filing occurs while the stock is trading above its 52-week high, suggesting profit-taking.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADPT was trading at $22.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $9.96 to $22.54. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.